Clinical trials: Autoimmune State
Rheumatoid Arthritis (RA)
Phase IIIB Subcutaneous Abatacept Monotherapy Study
To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept
- Trial name
- NCT00547521
- Testing
- abatacept, Methotrexate (MTX)
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 119 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.
- Trial name
- NCT00254293
- Testing
- Abatacept
- Where
- 5 sites in United States
- Volunteers
- 87 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
The purpose of this study is to assess whether co-administration of belimumab and a single cycle of rituximab will optimize treatment with belimumab, which will result in improvements of clinical status with a favorable safety…
- Trial name
- NCT03312907
- Testing
- Belimumab, Rituximab, Standard therapy (Including Immunosuppressants)
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus (SLE)
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will evaluate how well elsubrutinib and upadacitinib given alone or as the ABBV-599 combination…
- Trial name
- NCT04451772
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 87 sites in United States, Argentina and 16 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis
This is a phase 2a study to be run in 2-3 countries in European Union involving 5-6 sites. It will enroll approximately 80 patients to ensure 40 randomized with active rheumatoid arthritis.
- Trial name
- NCT03368235
- Testing
- AZD9567, Prednisolone
- Where
- 5 sites in Netherlands, Sweden
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)
The purpose of this study is to compare adherence, persistence, and effectiveness among patients initiating tofacitinib Modified Release (MR) with tofacitinib Immediate Release (IR).
- Trial name
- NCT04018001
- Where
- United States
- Volunteers
- 1,057 people
- Sponsor
- Pfizer
Autoimmune Diseases
A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses
GSK2982772 is a first-in-class, highly selective, receptor-interacting protein-1 (RIP1) kinase inhibitor being developed for the treatment of inflammatory bowel disease, plaque psoriasis (PsO), rheumatoid arthritis (RA) and other…
- Trial name
- NCT03266172
- Testing
- GSK2982772 Modified Release, GSK2982772 Immediate Release
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA
This study involves Rheumatoid Arthritis patients in regular clinical setting who are already on etanercept treatment and are in remission or in a low disease activity (LDA) state, and is intended to identify parameters that can…
- Trial name
- DOSERA (NCT00858780)
- Testing
- Etanercept
- Where
- 16 sites in Denmark, Finland and 4 more
- Volunteers
- 91 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX
To address the objectives, a retrospective cohort design will be employed to evaluate patient characteristics, treatment patterns, medication effectiveness, and health care cost and utilization in RA patients newly initiating…
- Trial name
- NCT03975790
- Where
- United States
- Volunteers
- 479 people
- Sponsor
- Pfizer
Arthritis, Juvenile Rheumatoid
Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients.
- Trial name
- NCT00637780
- Testing
- Sulfasalazine
- Where
- 2 sites in United States, Mexico
- Volunteers
- 2 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699
This FTIH study, intends to identify the doses of GSK3358699, which are well tolerated by the subjects whilst delivering a robust pharmacodynamic (PD) response.
- Trial name
- NCT03426995
- Testing
- GSK3358699, GM-CSF, LPS
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with Type 1 diabetes (T1D) followed by a 2-year safety follow-up.
- Trial name
- SUNRISE (NCT03895437)
- Testing
- TOL-3021
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- Tolerion, Inc.
Systemic Lupus Erythematosus
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE…
- Trial name
- NCT00724867
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Where
- 51 sites in United States
- Volunteers
- 268 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Arthritis, Rheumatoid
Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics
To compare rheumatoid arthritis (RA) patient characteristics, adherence, and costs between patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs.
- Trial name
- NCT03964649
- Where
- United States
- Volunteers
- 7,308 people
- Sponsor
- Pfizer